Abstracts tagged "giant cell arteritis"

Abstract Number: 2354 • 2012 ACR/ARHP Annual Meeting
The Prevalence of Low Bone Mineral Density in Patients with New Onset Giant Cell Arteritis. Do They Get Appropriate Bone Protective Treatment?
Andreas P. Diamantopoulos and Glenn Haugeberg, Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway
Background/Purpose: Giant cell arteritis (GCA) is a common form of vasculitis mainly affecting individuals older than 50 years with a mean onset age of 69…
Abstract Number: 2355 • 2012 ACR/ARHP Annual Meeting
Increase in Duration and Cumulative Dose of Glucocorticoid Therapy in Recent Decades: Observations From a Population-Based Cohort of Patients with Giant Cell Arteritis
P. Deepak Udayakumar¹, Tanaz A. Kermani², Kenneth J. Warrington³, Cynthia S. Crowson⁴ and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, University of California Los Angeles, Santa Monica, CA, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Systemic glucocorticoid (GC) therapy is the first line treatment for giant cell arteritis (GCA). Patients with GCA are often counseled that therapy will be…
Abstract Number: 2357 • 2012 ACR/ARHP Annual Meeting
Relapses in Patients with Giant-Cell Arteritis: Prevalence, Characteristics and Associated Clinical Findings in a Prospectively Followed Cohort of 106 Patients
Marco A. Alba¹, Ana García-Martínez², Itziar Tavera-Bahillo¹, Sergio Prieto-González¹, Montserrat Butjosa³, Georgina Espígol⁴, Marc Corbera⁴, Ester Planas⁴, Jose Hernandez-Rodriguez⁵ and Maria C. Cid⁶, ¹Systemic Autoimmune Diseases, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ²Department of Emergency Medicine, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ³Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clinic University Barcelona, Barcelona, Spain, ⁴Systemic Autoimmune Diseases, Vasculitis research unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁵Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁶Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: In spite of the satisfactory initial response to glucocorticoid treatment, patients with giant cell arteritis (GCA) frequently experience relapses during follow-up. The objectives of…
Abstract Number: 2359 • 2012 ACR/ARHP Annual Meeting
Outcome of Aortic Involvement in GIANT CELL Arteritis (GCA) After 1-Year Follow-up: Prospective Study in 35 Patients Using Computed Tompography Angiography (CTA)
Sergio Prieto-González¹, Pedro Arguis², Ana García-Martínez³, Itziar Tavera-Bahillo¹, Marc Corbera-Bellalta¹, Marco A. Alba¹, Georgina Espígol-Frigolé¹, Ester Planas-Rigol¹, José Hernández-Rodríguez¹ and Maria C. Cid⁴, ¹Systemic Autoimmune Diseases, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ²Center for diagnostic imaging, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ³Department of Emergency Medicine, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁴Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: 65% of patients with newly diagnosed, biopsy-proven GCA showed radiologic finding of aortitis using CTA in a prospective study of 40 patients. By segments,…
Abstract Number: 2360 • 2012 ACR/ARHP Annual Meeting
Prevalence, Management and Outcomes of PET Positive Large Vessel Vasculitis in Difficult to Treat PMR and GCA Patients
Pravin Patil¹, Shaifali Jain², Katerina Achilleos³, Tochukwu Adizie¹, Mark Williams¹, Matthew Tam² and Bhaskar Dasgupta⁴, ¹Rheumatology, Southend University Hospital, Westcliff on sea, United Kingdom, ²Radiology, Southend University Hospital, Westcliff on sea, United Kingdom, ³Rheumatology, Southend University Hospital, Westcliff-on-sea, United Kingdom, ⁴Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom
Background/Purpose: Management of PMR and GCA can be challenging in patients with persistently elevated inflammatory markers, prominent constitutional symptoms and inadequate steroid response. We undertook…
Abstract Number: 859 • 2012 ACR/ARHP Annual Meeting
Endothelin-1 (ET-1) Induces Extracellular Matrix Protein Production by Human Temporal Artery Derived Myointimal Cells. A Mechanism Potentially Leading to Intimal Hyperplasia and Vascular Occlusion in Giant-Cell Arteritis
Ester Planas-Rigol¹, Marc Corbera-Bellalta², Marco A. Alba³, Itziar Tabera-Bahillo³, Sergio Prieto-Gonzalez³, Georgina espigol-Frigole³, Jose Hernandez-Rodriguez⁴, Ester Lozano⁵ and Maria C. Cid⁶, ¹Systemic Autoimmune Diseases, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ²Hospital Clinic University Barcelona, Hospital Clinic University Barcelona, Barcelona, Spain, ³Vasculitis research Unit, systemic autoimmune diseases department. Idibaps., Hospital Clinic University Barcelona, Barcelona, Spain, ⁴Vasculitis research Unit, systemic autoimmune diseases department. Idibaps., Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁵Vasculitis research Unit, systemic autoimmune diseases department. Idibaps., Hospital Clinic University Barcelona, ⁶Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: Endothelin-1 (ET-1) is the main isoform of the Endothelin family. It is also the most powerful vasoconstrictor identified. ET-1 is constitutively produced in blood…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].